Exchange Traded Concepts LLC Trims Stake in Medpace Holdings, Inc. $MEDP

Exchange Traded Concepts LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 41.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,597 shares of the company’s stock after selling 1,130 shares during the period. Exchange Traded Concepts LLC’s holdings in Medpace were worth $821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wasatch Advisors LP boosted its position in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. boosted its position in Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares in the last quarter. AQR Capital Management LLC boosted its position in Medpace by 15.1% during the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock valued at $193,269,000 after purchasing an additional 81,637 shares in the last quarter. TD Asset Management Inc grew its stake in Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after purchasing an additional 61,764 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after purchasing an additional 45,435 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by insiders.

Medpace Trading Down 0.8%

Shares of MEDP stock opened at $567.56 on Monday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The stock has a market cap of $15.99 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.14 and a beta of 1.43. The stock has a 50 day moving average of $579.62 and a 200 day moving average of $482.65.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.Medpace’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Truist Financial set a $555.00 target price on shares of Medpace in a research note on Monday, October 27th. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Barclays increased their price objective on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Medpace has an average rating of “Hold” and an average price target of $490.82.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.